---
title: "SLU-PP-915: Research & Side Effects | BodyHackGuide"
url: https://www.bodyhackguide.co/compound/slu-pp-915
description: "SLU-PP-915: mechanism, clinical studies & side effects, 6 PubMed results. Compare 1 current vendor prices."
lang: en
---

Skip to content

Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide)

# SLU-PP-915

Metabolic: https://www.bodyhackguide.co/wiki#cat-metabolic

Status

Preclinical,, not approved for human use

Evidence

Not graded on a research bench yet

SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle.

Reviewed 27 October 2026

01 Overview

## What SLU-PP-915 is

It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it.

Read the full overview Show less

It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903).

SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886).

The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047).

Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687).

Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.

### How it works

SLU-PP-915 is a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, orphan nuclear receptors that drive transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle and are required for skeletal muscle adaptation to aerobic exercise. It came from a 2,5-disubstituted thiophene series designed around ERR-gamma, in which a boronic acid group replaced phenol or aniline to improve microsomal stability while keeping potency across all three subtypes; the compound upregulates the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 in vitro and in vivo (PMID: 37421886). In mice it induces Ddit4, an acute aerobic exercise response gene, at levels comparable with treadmill running and increases running distance and duration by oral and intraperitoneal routes (PMID: 41421047).

### Studied for

- Estrogen-related receptors
- Exercise mimetics
- Mitochondrial biogenesis
- Sports drug testing

### Benefits listed

- Increased aerobic exercise distance and duration in mice by oral and by injected administration (PMID: 41421047)
- Induced the acute aerobic exercise response gene Ddit4 in mouse muscle at levels matching or exceeding treadmill running (PMID: 41421047)
- Increased mitochondrial gene expression further when combined with exercise training in mice (PMID: 41421047)
- Upregulated the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 in cells and in vivo (PMID: 37421886)

Show 1 more Show less

- In the closely related pan-ERR agonist SLU-PP-332, increased energy expenditure and fatty acid oxidation with reduced fat mass and improved insulin sensitivity in obese mice (PMID: 37739806)

02 Research

Free with email

## What the research shows

No research bench grades SLU-PP-915 yet. Benches compare compounds people pair, with the evidence for each.

### Unlock the research summary

Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

- A summary of the key research
- Safety and side effects
- A link to the PubMed results

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in (https://www.bodyhackguide.co/auth)

03 Safety

## SLU-PP-915 side effects and interactions

### Side effects

Not in our record

Our record lists no side effects for SLU-PP-915. That means none are recorded here, not that there are none. The Research section has the written safety notes.

### Who should not use it

Contraindications

None can be stated from evidence, because no human has been studied. Mechanism-based caution applies broadly: ERR agonism alters mitochondrial and metabolic gene transcription across muscle, heart, kidney and liver (PMID: 37961903; PMID: 37717940), and no organ safety margin has been established in any species at doses relevant to human use. No reproductive, developmental, hepatic or renal safety data exist.

### Interactions

Not in our record

Our record lists no interactions for SLU-PP-915. That means none are recorded here, not that none exist.

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

Order Bloodwork (https://anabolicinsights.ai/?ref=nwm2zjb)

04 Dosing

Free with email

## Dosing

No dose on record

Our record lists no dose for SLU-PP-915. This section holds what it does list.

### Unlock the Dosing section

- Route

05 Prices

## SLU-PP-915 prices

1 listing from 1 vendor, opening in the Featured order.

Pack prices

$139.99

Lowest per mg

$0.233/mg

Vendors

1

Listings

1 (capsule)

Prices as the vendors list them, last recorded 7 September 2026.

Form

Sort

| Vendor | Product | Price | Buy |
| --- | --- | --- | --- |
| Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/uploads/2026/10/disguised-logo-3x.webp) Disguised Alpha: https://www.bodyhackguide.co/vendors/disguised-alpha | SLU-PP-915 10 mg capsules (60) capsule, 60 capsules (10 mg) In stock | $0.233/mg $139.99 Lowest per mg | Buy SLU-PP-915 10 mg capsules (60) at Disguised Alpha: https://disguisedalpha.com/product/slu-pp-915-10mg-capsules/?coupon=reddit |

Vendors selling SLU-PP-915(1: trust score, certificates, payment, shipping)

- Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha)1 listing, from $139.99
  Trust Score 50/100 (https://www.bodyhackguide.co/vendor-trust-scorecard), 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK

Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors (https://www.bodyhackguide.co/vendors/scorecard)

Review SLU-PP-915

### Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with SLU-PP-915.

06 Chemistry

## Chemistry and structure

Molecular formula

C17H13BFNO3S

Molecular mass

341.16 g/mol

CAS number

2285432-92-8

Half-life

Not established in humans; in mice it is orally bioavailable and active by both oral and intraperitoneal routes, unlike its predecessor SLU-PP-332 (PMID: 41421047)

View on PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/142532359)

07 Related

## Related to SLU-PP-915

### In the same category

- AICAR (acadesine)Phase 3 AICAR is a nucleoside analog of adenosine.: https://www.bodyhackguide.co/compound/aicar
- AmlexanoxFDA Approved Amlexanox is an old anti-inflammatory drug with a second life.: https://www.bodyhackguide.co/compound/amlexanox
- BerberineDietary Supplement Berberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi).: https://www.bodyhackguide.co/compound/berberine
- Cardarine (GW501516)Discontinued Cardarine is the market name for GW501516, a synthetic agonist of the nuclear receptor PPAR-delta developed by GlaxoSmithKline as a treatment for low HDL cholesterol and the lipid problems that travel with metabolic syndrome.: https://www.bodyhackguide.co/compound/cardarine
- MetforminPreclinical Metformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually.: https://www.bodyhackguide.co/compound/metformin
- Sobetirome (GC-1)Discontinued Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor.: https://www.bodyhackguide.co/compound/sobetirome

All compounds (https://www.bodyhackguide.co/wiki)

### Compare SLU-PP-915

- Alternatives to SLU-PP-915: https://www.bodyhackguide.co/alternatives-to/slu-pp-915

### Research tools

- Peptide Calculator Reconstitution and syringe units: https://www.bodyhackguide.co/tools/reconstitution
- Reconstitution Guide How to mix, step by step: https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides
- Nasal Spray Calc mL per actuation: https://www.bodyhackguide.co/tools/intranasal
- Half-Life Visualizer Decay curves: https://www.bodyhackguide.co/tools/halflife

All articles (https://www.bodyhackguide.co/blog)

08 Questions

## Frequently asked questions

What is SLU-PP-915 used for in research?

SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it.

What forms does SLU-PP-915 come in?

SLU-PP-915 is available in capsule form.

How do I compare SLU-PP-915 vendors?

Compare prices, payment methods, shipping, and COA scores across 1 vendor.

How many vendors sell SLU-PP-915, and what does it cost per mg?

1 of the vendors BodyHackGuide tracks list SLU-PP-915 (1 listing). Among BodyHackGuide's SLU-PP-915 listings recorded as in stock with a milligram count, the lowest price per milligram is $0.233/mg at Disguised Alpha and the median is $0.233/mg. The SLU-PP-915 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a SLU-PP-915 listing is dated 7 September 2026.

Which vendors have third-party COAs for SLU-PP-915 on file at BodyHackGuide?

BodyHackGuide holds 4 third-party certificate records for SLU-PP-915, from Disguised Alpha. No editor has read any of BodyHackGuide's 4 certificate records for SLU-PP-915. The laboratory named on BodyHackGuide's SLU-PP-915 certificate records is Freedom Diagnostics Testing, and the newest test date on them is 2 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

Free 2026 Peptide Cheat Sheet (PDF)

38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download)

BodyHackGuide (https://www.bodyhackguide.co/)

Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews.

support@bodyhackguide.co

Join our Discord: https://discord.gg/Mhq5UdRYBA
r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide

**Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved.

- Terms: https://www.bodyhackguide.co/terms
- Privacy: https://www.bodyhackguide.co/privacy

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://www.bodyhackguide.co/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Compounds",
        "item": "https://www.bodyhackguide.co/compare"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "SLU-PP-915"
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "Product",
    "name": "SLU-PP-915",
    "description": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.",
    "url": "https://www.bodyhackguide.co/compound/slu-pp-915",
    "image": "https://www.bodyhackguide.co/og-image.png",
    "brand": {
      "@type": "Brand",
      "name": "Research Compound"
    },
    "offers": {
      "@type": "AggregateOffer",
      "lowPrice": "139.99",
      "highPrice": "139.99",
      "priceCurrency": "USD",
      "offerCount": "1",
      "availability": "https://schema.org/InStock",
      "offers": [
        {
          "@type": "Offer",
          "price": "139.99",
          "priceCurrency": "USD",
          "availability": "https://schema.org/InStock",
          "itemCondition": "https://schema.org/NewCondition",
          "url": "https://disguisedalpha.com/product/slu-pp-915-10mg-capsules/?coupon=reddit",
          "seller": {
            "@type": "Organization",
            "name": "Disguised Alpha",
            "url": "https://disguisedalpha.com/?coupon=reddit"
          },
          "name": "SLU-PP-915 600mg capsule"
        }
      ]
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "SLU-PP-915",
    "description": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.",
    "lastReviewed": "2026-10-27T07:11:00+00:00",
    "url": "https://www.bodyhackguide.co/compound/slu-pp-915",
    "author": {
      "@type": "Person",
      "name": "BioChonch",
      "url": "https://www.bodyhackguide.co/about",
      "jobTitle": "Founder & Lead Researcher",
      "sameAs": [
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher"
      ],
      "worksFor": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      }
    },
    "reviewedBy": {
      "@type": "Person",
      "name": "BioChonch",
      "url": "https://www.bodyhackguide.co/about",
      "jobTitle": "Founder & Lead Researcher",
      "sameAs": [
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher"
      ],
      "worksFor": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      }
    },
    "publisher": {
      "@type": "Organization",
      "name": "BodyHackGuide",
      "url": "https://www.bodyhackguide.co"
    },
    "mainContentOfPage": {
      "@type": "WebPageElement",
      "cssSelector": "main"
    },
    "about": {
      "@type": "Drug",
      "name": "SLU-PP-915",
      "alternateName": [
        "SLU-PP-915",
        "SLUPP915",
        "pan-ERR agonist SLU-PP-915",
        "ERR agonist 10s"
      ],
      "description": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.",
      "activeIngredient": "SLU-PP-915",
      "administrationRoute": "Oral (rodent studies), Intraperitoneal injection (rodent studies)",
      "mechanismOfAction": "SLU-PP-915 is a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, orphan nuclear receptors that drive transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle and are required for skeletal muscle adaptation to aerobic exercise. It came from a 2,5-disubstituted thiophene series designed around ERR-gamma, in which a boronic acid group replaced phenol or aniline to improve microsomal stability while keeping potency across all three subtypes; the compound upregulates the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 in vitro and in vivo (PMID: 37421886). In mice it induces Ddit4, an acute aerobic exercise response gene, at levels comparable with treadmill running and increases running distance and duration by oral and intraperitoneal routes (PMID: 41421047).",
      "dosageForm": "capsule",
      "legalStatus": "Not approved for human use (research chemical)",
      "warning": "For research purposes only. Not for human consumption."
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "FAQPage",
    "mainEntity": [
      {
        "@type": "Question",
        "name": "What is SLU-PP-915 used for in research?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it."
        }
      },
      {
        "@type": "Question",
        "name": "What forms does SLU-PP-915 come in?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "SLU-PP-915 is available in capsule form."
        }
      },
      {
        "@type": "Question",
        "name": "How do I compare SLU-PP-915 vendors?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor."
        }
      },
      {
        "@type": "Question",
        "name": "How many vendors sell SLU-PP-915, and what does it cost per mg?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "1 of the vendors BodyHackGuide tracks list SLU-PP-915 (1 listing). Among BodyHackGuide's SLU-PP-915 listings recorded as in stock with a milligram count, the lowest price per milligram is $0.233/mg at Disguised Alpha and the median is $0.233/mg. The SLU-PP-915 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a SLU-PP-915 listing is dated 7 September 2026."
        }
      },
      {
        "@type": "Question",
        "name": "Which vendors have third-party COAs for SLU-PP-915 on file at BodyHackGuide?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "BodyHackGuide holds 4 third-party certificate records for SLU-PP-915, from Disguised Alpha. No editor has read any of BodyHackGuide's 4 certificate records for SLU-PP-915. The laboratory named on BodyHackGuide's SLU-PP-915 certificate records is Freedom Diagnostics Testing, and the newest test date on them is 2 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page."
        }
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "@id": "https://www.bodyhackguide.co#organization",
    "name": "BodyHackGuide",
    "alternateName": "BHG",
    "url": "https://www.bodyhackguide.co",
    "logo": {
      "@type": "ImageObject",
      "url": "https://www.bodyhackguide.co/logo.png",
      "width": 512,
      "height": 512
    },
    "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.",
    "foundingDate": "2024",
    "founder": {
      "@id": "https://www.bodyhackguide.co/about#person"
    },
    "sameAs": [
      "https://reddit.com/r/BodyHackGuide",
      "https://reddit.com/r/BrainHackGuide",
      "https://reddit.com/r/Biohackingher",
      "https://discord.gg/Mhq5UdRYBA"
    ],
    "knowsAbout": [
      "Peptide research",
      "Nootropic research",
      "Biohacking",
      "Compound dosing",
      "Vendor transparency"
    ],
    "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
    "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
    "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
  }
]
```